Severity (pain) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Severity of attack of recurrent herpes labialis during use of the preventative intervention (duration of pain) · participants with recurrent herpes labialis
1 finding from 1 review
Pain · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · adults with basal cell carcinoma of the skin
MAL‐PDT showed no clear difference in pain compared with surgical excision (low certainty).
1 finding from 1 review
Pain · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in Pain VAS · participants with hidradenitis suppurativa
1 finding from 1 review
Pain reduction (VAS) · People with erosive oral lichen planus
Topical clobetasol propionate 0.025% showed no clear difference in pain reduction (VAS) compared with topical clobetasol propionate 0.05%; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS) · People with erosive oral lichen planus
1% pimecrolimus cream showed no clear difference in pain reduction (VAS) compared with placebo (vehicle cream); GRADE not reported.
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod cream probably leads to lower pain (moderate/severe) compared with MAL‐PDT (moderate certainty).
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod showed no clear difference in pain (moderate/severe) compared with surgical excision (low certainty).
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Clobetasol propionate ointment 0.05% showed no clear difference in pain reduction (VAS 0-10) compared with 5% topical mesalazine gel in adhesive base; GRADE not reported.
1 finding from 1 review
Pain VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase led to higher pain reduction (VAS 0-100) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
1 finding from 1 review
In the Hegarty 2002 cross-over trial (n=22), no statistical testing of the pain score (VAS 0 to 100) was reported; it is not clear whether the difference is statistically significant (fluticasone mean score 19.8 versus…
1 study · 22 participants
GRADE not reported
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
Clobetasol-17-propionate 0.025% lipid-loaded microspheres led to lower pain reduction (VAS 0-100) compared with conventional 0.025% clobetasol lipophilic ointment in hydrophilic…; GRADE not reported.
1 finding from 1 review
Proportion with improvement in pain · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion with improvement in pain compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · People with erosive oral lichen planus
Topical ciclosporin 1.5% gel showed no clear difference in pain (>=50% improvement in symptoms) compared with topical clobetasol propionate 0.025% gel; GRADE not reported.
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · People with erosive oral lichen planus
Aloe vera gel led to higher pain (>=50% improvement in symptoms) compared with placebo; GRADE not reported.
1 finding from 1 review
Proportion with improvement in pain VAS · participants with hidradenitis suppurativa
Adalimumab weekly probably leads to higher proportion with improvement in pain VAS compared with placebo (moderate certainty).
1 finding from 1 review